Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 501–600 of 1,139
Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs
Kim, S. Y., Won, S. E., Park, H. J., Woo, C.-Y., Kim, D. W., Suh, C. H., & Kim, K. W. (2026) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0937 · Cited by 6
“…polypeptide, glucagon-like peptide 1, and glucagon receptors) currently awaiting U.S. FDA approval for use as a treatment for obesity [85], was investigated in a phase IIa trial involving patients with metabolic dysfunction– associated steatotic liver disease (MASLD) using the…”
The First Triple Agonist for Antiobesity: Retatrutide
Tetelbaun, L., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000793 · Cited by 6
Management of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
“55 The next-generation triple GLP-1/glucose-dependent insulinotropic polypeptide/glucagon receptor coagonist, retatrutide, has demonstrated additional lipid and blood pressure-lowering effects, further supporting its therapeutic role in MASLD and CKD. 56 These drugs provide direct kidney protection through anti-inflam…”
InfluentialObesity and its treatment: Toward new approaches
Segrestin, B., & Cherifi, B. G. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101712 · Cited by 7
Four key questions on the new wave of anti-obesity drugs
Prillaman, M. (2023) · Nature · doi:10.1038/d41586-023-02445-4 · Cited by 7
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Hope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
“13 More recently, GLP-1R/GIPR/GCGR triple agonists such as SAR441255 14 and retatrutide/LY3437943 15,16 have been tested in clinical trials.”
An RNA-seq atlas of mouse brain areas during fasting and diet-induced obesity
Todorov, P. V., Klein, A. B., Egerod, K. L., Clemmensen, C., & Pers, T. H. (2024) · Scientific Data · doi:10.1038/s41597-023-02888-4 · Cited by 5
Management of Adult Obstructive Sleep Apnoea: Many Questions, Not Enough Answers!
Stanczyk, M., McNicholas, W. T., Pevernagie, D., Riha, R. L., & Ryan, S. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70047 · Cited by 7
Petersen, E. A., Blom, I., Melander, S. A., Al-Rubai, M., Vidotto, M., Dalgaard, L. T., Karsdal, M. A., Henriksen, K., Larsen, S., & Larsen, A. T. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01564-w · Cited by 8
“Incretin-based therapies such as Semaglutide and Tirzepatide have demonstrated successful anti-obesity properties in both preclinical and clinical trials [6 – 8].”
EndoBridge 2023: highlights and pearls
Yıldız, B. O., Boguszewski, C. L., Boguszewski, M. C. D. S., Busetto, L., Celik, O., Fuleihan, G. E., Goulis, D. G., Hammer, G. D., Haymart, M. R., Kaltsas, G., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00549-8 · Cited by 5
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[160] In the treatment of obesity, retatrutide has demonstrated significant weight loss effects in multiple clinical trials.”
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Recognizing overweight and obesity as chronic diseases and acknowledging root causes
Falahee, B. E., Kim, D. W., & Apovian, C. M. (2025) · Med · doi:10.1016/j.medj.2025.100782 · Cited by 5
Obesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Xu, B., Gaynor-Sodeifi, K., & Kundel, V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03312-6 · Cited by 6
Applebey, S. V., Xiao, A. G., Harris, E. P., Levine, C. M., Belser, D. L., Geisler, C. E., Parent, M. B., Bangasser, D. A., Crist, R. C., Reiner, B. C., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.01.012 · Cited by 6
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Impact of dairy food products on type 2 diabetes: Gut-pancreas axis for lower glucose level
Ağagündüz, D., Yılmaz, B., Cemali, Ö., Šimat, V., Akkuş, G., Kulawik, P., & Özoğul, F. (2024) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2024.104741 · Cited by 7
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“Dual GLP-1-GIP (e.g., tirzepatide [255]), dual GLP-1-glucagon (e.g., sur-vodutide, efinopegdutide, BI456906 [256, 257]) or triple GLP1-GIP-glucagon (e.g., retatrutide [258]) agonists are currently being tested (Phase II/III trials) in patients with Obesity, T2DM and/or MASLD [4].”
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 14
“…GLP-1RAs in patients with MASLD/MASH include gastrointestinal symptoms (nausea, vomiting diarrhea, constipation or abdominal discomfort), a profile consistent with that observed in previous phase 3 clinical trials involving patients with T2DM, obesity or both [110, 112–114, 120, 122–124, 126–129].”
InfluentialWu, Y., Foollee, A., Chan, A. Y., Hille, S. S., Hauke, J., Challis, M. P., Johnson, J. L., Yaron, T. M., Mynard, V., Aung, O. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52703-w · Cited by 8
“Aside from this, and spurred on by promising pre-clinical studies 8 – 11 , peptides with glucagon receptor agonist activity are in development for treating obesity and type 2 diabetes in humans 12,13 .”
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Ji, L., Gao, L., Tian, J., DONG, R., Zhang, Z., Shu, H., Zhao, J., Zhao, L., He, A., Xie, T., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02586-8 · Cited by 6
“27,28 These events occurred predominantly during the early dose-escalation period and gradually decreased over time, which aligns with the fi ndings observed in the phase 2a trial and indicates the tolerance process.”
InfluentialEffect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside
O’Donnell, C., King, A., Vial, G., O'Neill, E., Crilly, S., Dodd, J. D., Murphy, D. J., Belaïdi, E., Pépin, J., Arnaud, C., et al. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70152 · Cited by 6
From obesity to cardiovascular disease: pathological basis and clinical implications
Nardin, M., Mehran, R., Oliva, A., Kedhi, E., Galasso, G., Nardin, S., Savonitto, S., Condorelli, G., & Luca, G. D. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.041 · Cited by 7
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Tirzepatide-Induced Liver Injury: A Rare Complication
Spaeth, L. D., Jordan, K. M., Barlow, M., & Cottrell, D. A. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.009 · Cited by 5
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch07 · Cited by 5
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“Phase 2 results suggest remarkable weight loss trajectories, that approach or exceed 20-24% (8 and 12 mg) at 48 weeks, putting retatrutide on track to potentially replace the existing incretin-dominated standard of care [43].”
From genes to care: the expanding therapeutic horizon in rare genetic obesities
Chalopin, S., Guillon, E., Faucher, P., Dubern, B., Clément, K., & Poitou, C. (2025) · Obesity and Endocrinology · doi:10.1093/obendo/wjaf007 · Cited by 4
Madigan, C. D., King, J. A., Taylor, C., Hoekstra, S. P., Graham, H. E., Kirk, N., Fenton, J. M., & Goosey-Tolfrey, V. L. (2024) · Obesity Reviews · doi:10.1111/obr.13785 · Cited by 6
Jewell, M. L. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad263 · Cited by 4
Jimenez, L., Múñoz, Ó., Alfonso, D., & Medina, A. M. G. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02118-y · Cited by 15
Molecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non–Small Lung Cancer
Dingemans, A. C., Mathijssen, R. H. J., & van Rossum, E. F. C. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.014 · Cited by 4
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“Retatru-tide [50] is a novel triple agonist that targets GIP, GLP-1, and glucagon receptors.”
InfluentialAyesh, H., Ayesh, S., & Niswender, K. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001743 · Cited by 4
Molecular design of peptide therapeutics via N-terminal modification
Sürmeli, D., Dinsmore, T. C., Anchukaitis, H. M., Montanari, V., Beinborn, M., & Kumar, K. (2024) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2024.04.011 · Cited by 7
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Alsanea, S., Alkofide, H., Almadi, B., Almohammed, O. A., Alwhaibi, A. M., Alrabiah, Z., & Kalagi, N. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.009 · Cited by 5
Ellberg, C. C., Schwartz, H. R., Witt, A., McCowen, K. C., Fuentes, A. L., & Malhotra, A. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00384-1 · Cited by 6
“Other agents such a triple-hormone receptor agonist retatrutide (agonist of GLP1-RA, GIP and glu - cagon) are also being investigated [60]. b) Can long term studies be undertaken to determine if the observed results in SURMOUNT-OSA are sustained over time?”
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 100%, 93%, and 83%, respectively, of those who received 12 mg (the highest dose); compared to 27%, 9%, and 2% weight reduction in those who received placebo [398].”
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
The role of glucagon after bariatric/metabolic surgery: much more than an “anti-insulin” hormone
Pérez-Arana, G.-M., Díaz-Gómez, A., Reyes, J. B.-D. L., Romero, M. Á. G., Ribelles-García, A., Visiedo, F., González‐Domínguez, Á., Gomar, D. A., & Oliveira, J. A. P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236103 · Cited by 8
“However, it also presented a series of adverse gastrointestinal events, although limited to patients treated with high doses (37).”
BackgroundGenetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review
Kavaja, F., Liehr, T., & Temaj, G. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15484 · Cited by 6
“Using retatrutide is also shown to improve several cardiometabolic parameters and it demonstrates a favorable safety profile with comparable rates of adverse events to placebo (Jastreboff et al., 2023; Naeem et al., 2024).”
InfluentialImpact of medical versus surgical weight loss on cardiovascular outcomes
Ostapenko, A., & Ahmed, B. H. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.004 · Cited by 5
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
“In a phase 2 clinical trial, participants receiving retatrutide achieved up to 24.2% mean weight loss over 48 weeks, exceeding both semaglutide and tirzepatide [166].”
InfluentialEckert, D. J. (2025) · Drugs · doi:10.1007/s40265-025-02268-9 · Cited by 7
“This includes the triple target weight loss agent retatrutide [94], which is currently under investigation with OSA severity as the primary outcome in people with (ClinicalTrials.gov identifier: NCT05929079) and without (NCT05929066) diabetes.”
Gut hormone stimulation as a therapeutic approach in oral peptide delivery
Beloqui, A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.007 · Cited by 4
Heerspink, H. J. L., van Raalte, D. H., Bjornstad, P., Bunck, M. C. M., Wu, P., Tunali, I., Miličević, Z., & Koeneman, L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf230 · Cited by 9
“In two Phase 2 clinical trials in participants with T2D and in participants with overweight or obesity without T2D, retatrutide improved glycemic control and reduced body weight along with reductions in blood pressure, cholesterol and markers of inflammation [13 , 14 ].”
Self-citationHo, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
Viebahn, G., Khurana, A., Freund, L., Chilin-Fuentes, D., Jepsen, K., Rosenthal, S. B., Chatterjee, S., Ellenrieder, V., Hsu, C. L., Schnabl, B., et al. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00164.2025 · Cited by 5
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners
Kesavadev, J., Basanth, A., Shankar, A., Saboo, B., Mohan, A. R., Joshi, S., Ghosh, S., Krishnan, G., Jothydev, K., & Ashik, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03250-3 · Cited by 8
“Notably, a Phase II trial dedicated to treating obesity demonstrated a noteworthy 24% reduction in body weight over a 48-week period [46].”
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics
Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 7
“To improve metabolic outcomes, current research is also exploring the potential of multi-receptor agonists, such as tirzepatide, the first FDA-approved GIP/GLP-1 dual receptor agonists [179–181], and retatrutide, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors [182,183].”
Yoo, S., Yoo, E.-S., Kim, J. I., & Sohn, J. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2185 · Cited by 4
Doiron, J. E., Elbatreek, M. H., Xia, H., Yu, X., Gehred, N. D., Gromova, T., Chen, J., Driver, I. H., Muraoka, N., Jensen, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.16.613349 · Cited by 4
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
Advances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
“Phase 2 results indicated marked clinical benefits for T2D [61] and obese [45] patients exceeding those seen with tirzepatide (Table 1).”
BackgroundResultSlattery, J. D., Rambousek, J. R., Tsui, E. W., Honeycutt, M. K., Goldberg, M., Graham, J. L., Wietecha, T., Wolden‐Hanson, T., Williams, A. L., O’Brien, K. D., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503096 · Cited by 5
Feetham, C. H., Groom, S., John, L. M., Christoffersen, B. Ø., Collabolletta, V., Lyons, D., Adamson, A. D., Lundh, S. H., Gerstenberg, M. K., Tang‐Christensen, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.021 · Cited by 4
Testosterone Therapy in Adult Males with Hypogonadism
Boeri, L., Masterson, T., Antonio, L., Corona, G., Khera, M., Salonia, A., & Mulhall, J. P. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.015 · Cited by 10
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Raza, S. S., Zakir, Z., Hashmat, A., Awan, S. K., & Varrassi, G. (2025) · Cureus · doi:10.7759/cureus.96739 · Cited by 8
“Early trials of next-generation agents, oral small-molecule glucagon-like peptide 1 (GLP-1) agonists such as orforglipron and triple agonists such as retatrutide, show even greater or comparable efficacy and new routes of administration [7,8].”
Novel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease
Philip, J. S., Shah, A., & Avenatti, E. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01331-w · Cited by 3
Wong, N. D., Karthikeyan, H., & Fan, W. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07583-z · Cited by 3
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Drug approach to treatment for obesity in adults: perspectives and considerations
Escalada, J. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10206/2023 · Cited by 3
Advances in clinical research on glucagon
Horie, I., & Abiru, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00705-w · Cited by 3
“Dual agonists for glucagon and GLP-1 [85, 86] and triple agonists for glucagon, GIP, and GLP-1 [87] are under development as potential treatments for diabetes and obesity.”
ROSENSTOCK, J., Lingvay, I., RYAN, D. H., Jastreboff, A. M., Kushner, R., ACOSTA, A., Blevins, T., Choi, M., HOLMES, F. L., Smith, T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04476-6 · Cited by 9
Self-citationZhang, Y., Zhang, C., gong, X., cheng, P., Fu, H., Diao, L., & Song, C. (2026) · European journal of medical research · doi:10.1186/s40001-026-03933-9 · Cited by 13
“Three studies were treated with semaglutide (SME) [28–30], three with LIR [31–33], one with SME or LIR [34], one with oral semaglutide (OSM) [35], one with orforglipron (ORF) [36], two with tirzepatide (TZP) [37, 38] and one with retatrutide (RET) [39].”
Future Medications for Obesity and Clinical Implications
Garvey, W. T. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0004 · Cited by 3
Metabolic-Bariatric Surgery for Type 2 Diabetes: Time(ing) for a Change
Purnell, J. Q. (2024) · Diabetes · doi:10.2337/dbi23-0022 · Cited by 3
Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice
Moura‐Assis, A., Plucińska, K., Meseguer, D., Baleisyte, A., Chen, B., Pellegrino, K., Parolari, L., Shaked, J. T., Page, K. J., Barrows, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68056-x · Cited by 4
Improving incretin-mediated body weight loss via energy expenditure
Elmendorf, A. J., Douros, J. D., Knerr, P. J., & Flak, J. N. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.12.004 · Cited by 5
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 6
The history of the pharmacotherapy of obesity
Berkovskaya, M. A., Gurova, O. Y., Surkova, E. V., & Fadeev, V. V. (2025) · Problems of Endocrinology · doi:10.14341/probl13469 · Cited by 5
Gliozzi, M., Coppoletta, A. R., Cardamone, A., Carresi, C., Mollace, R., Musolino, V., & Mollace, V. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107744 · Cited by 3
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
Bays, H. E., Brown, C., & Fitch, A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100079 · Cited by 3
Eating- and Weight-Related Disorders in the Armed Forces
Himmerich, H., Gravina, D., Schalinski, I., Willmund, G., Zimmermann, P. L., Keeler, J. L., & Treasure, J. L. (2024) · Metabolites · doi:10.3390/metabo14120667 · Cited by 4
Goodman, J., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
“Retatrutide, a triple agonist at the GIP, GLP-1 and glucagon receptor increases heart rate and decreases blood pressure in obese adults 102 .”
Kanbay, M., Çöpür, S., Güldan, M., Özbek, L., Mallamaci, F., & Zoccali, C. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14330 · Cited by 4
“19,20 Moreover, a double-blind randomized multicentered phase II placebo-controlled clinical trial has evaluated the efficiency and safety of retatrutide therapy among obese or overweight participants among which 29.1% ( n = 98) patients have at least 10% liver fat content assessed via magnetic…”
InfluentialSachdev, S., Roy, S., & Cheloha, R. W. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003424 · Cited by 3
“For example, activation of glucagon family receptors (GLP1R, GIPR, GCGR) shows therapeutic efficacy in treating type-2 diabetes and obesity [49]; however, these receptors are expressed in multiple tissues [50].”
Lopes, T., Hope, D. C. D., Pittol, J. M. R., Curtis, A., Shrewsbury, J. V., Davies, I., Zhou, Z., Sardini, A., MINNION, J. S., Dormann, D., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102024 · Cited by 3
“Examples include the GLP-1/GIP/glucagon triple-agonist Reta-trutide and the GLP-1/glucagon co-agonist Survodutide [11,12].”
BackgroundGabery, S., Glendorf, T., Ballarín-González, B., Pedersen, K., Kruse, T., Raun, K., & Kuhre, R. E. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123845 · Cited by 4
Contractile effects of retatrutide in isolated mouse atrial preparations
Neumann, J., Ahlrep, U., Hofmann, B., & Gergs, U. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04335-0 · Cited by 3
Kanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
Self-citationBerković, M. C., Ružić, L., Cigrovski, V., & Strollo, F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.109123 · Cited by 10
Anti-obesity drugs for the gastroenterologist
Sharkey, L. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102995 · Cited by 4
“42 Given the potential extraordinary economic and composite health benefits to the individual and population, it seems likely that the area of Bariatric Pharmacology will continue to expand.”
Pedigo, J., Eastman, K. A. S., & Bandarian, V. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00152 · Cited by 3
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
“Retatrutide is a triple agonist targeting GLP-1, GCG, and GIP receptors, previously studied in patients with type 2 diabetes and obesity [26,27].”
Dennis, C. J., He, A. Z., Krishnaraj, A., Quan, A., Teoh, H., Connelly, K. A., Hess, D. A., & Verma, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327425 · Cited by 4
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.